Health Trials

Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma

ConditionsRelapsed/Refractory B-cell LymphomaDiffuse Large B-cell LymphomaInert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInstitute of Hematology & Blood Diseases Hospital, China

About this trial

This study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.

Eligibility criteria

Qualifiers

1. The participant has given consent and signed the informed consent form, and is willing and able to comply with the planned visits, research treatments, laboratory tests, and other trial procedures;

Anti-CD20 monoclonal antibody;

Combination chemotherapy containing anthracyclines.

3. Age 18 or older, both men and women are eligible;

Disqualifiers

1. Severe heart failure or left ventricular ejection fraction <50%;

2. History of severe pulmonary function impairment;

3. Concurrent other malignant tumors in the progressive stage;

4. Concurrent severe infection that cannot be effectively controlled;

Trial design

Treatments tested in this trial

  • CY-219 CAR-T

Treatment groups

18 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Institute of Hematology & Blood Diseases Hospital, China

Lead sponsor

Source ClinicalTrials.gov